



# Type 1 Diabetes Mellitus Immunotherapy: Using regulatory T cells to balance the immune response

Author: Raquel Crespo Galván

Microbiology Bachelor

Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease affecting millions of people worldwide. Immunoregulation may be achieved in many ways, one of the most promising is regulatory T cell therapy. Here will be discussed the numerous T1DM after-diagnosis therapies that are currently being involved in clinical trials or have proved to be effective in animal models.

Keywords: immunotherapy, regulatory T cells, Type 1 Diabetes Mellitus, autoimmunity



Since the Treg population is disbalanced in T1DM patients, immunotherapies increasing this population seem the fittest possibility for the disease reversion. Among all therapies discussed, only ex vivo T reg expansion has presented remarkable results and regulatory T cells are perfectly on guard and in higher numbers. The finding of a personalized treatment that could revert the disease represents the main objective of the diabetes scientific community.

### MAIN BIBLIOGRAPHY:

1. Peakman, M. & von Herrath, M. Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential. *Diabetes* 59, 2087–2093 (2010). 2. Bresson, D. & von Herrath, M. Immunotherapy for the Prevention and Treatment of Type 1 Diabetes. *Diabetes Care* 32, 1753–1768 (2009). 3. Rewers, M. & Gottlieb, P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. *Diabetes Care* 32, 1769–1782 (2009). 4. Colman, P. G. & Eisenbarth, G. S. Immunotherapy in type 1 diabetes. Approaches to prevention and treatment. *Postgrad. Med.* 81, 146–155 (1987). 5. Singer, B. D., King, L. S. & D'Alessio, F. R. Regulatory T cells as immunotherapy. *Front. Immunol.* 5, 46 (2014). 6. Cabrera, S. M., Rigby, M. R. & Mirmira, R. G. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. *Curr. Mol. Med.* 12, 1261–1272 (2012).